Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HER2
Pharma
Increased deaths shadow Enhertu’s first-line lung cancer data
Enhertu showed a preliminary 15% increased risk of death compared to Keytruda plus chemo in the Destiny-Lung04 study in first-line HER2-mutant NSCLC.
Angus Liu
Sep 13, 2026 7:00pm
Jazz’s Ziihera secures 2nd survival win in HER2+ stomach cancer
Aug 31, 2026 10:17am
Jazz’s Ziihera nets FDA nod in first-line HER2+ stomach cancer
Aug 25, 2026 11:06am
AstraZeneca dual lung cancer wins softened by bispecific fail
Aug 17, 2026 10:56am
BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC
Jul 9, 2026 2:17pm
Enhertu secures dual FDA approvals in early breast cancer
May 18, 2026 10:52am
